ArticleAmerican journal of cancer research2025
Factors influencing serum hCG negativization timing in gestational trophoblastic neoplasia.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gestational trophoblastic neoplasia (GTN) refers to malignant diseases originating from placental trophoblast cells. Despite high complete remission rates with standard treatments, the adverse effects of chemotherapy, variation in treatment regimens, and the psychological impact on patients significantly influence the prognosis. This study aims to identify factors influencing the time to serum human chorionic gonadotropin (hCG) negativization, thereby contributing to the optimization of patient management strategies. We conducted a retrospective analysis of 206 patients diagnosed with invasive mole and gestational choriocarcinoma treated at the First Affiliated Hospital of Zhejiang University School of Medicine from January 2014 to May 2022. Patients- and treatment-related risk factors were collected. We evaluated 33 variables potentially related to the duration of serum hCG negativization with statistically significant variables from univariate analyses subsequently included in multivariate Cox regression analysis. Through univariate analysis, we identified 11 significant predictors that related with hCG negativization, including body mass index (BMI), age at menarche, number of miscarriages, prior pregnancy status, time since prior pregnancy, maximum tumor diameter, maximum lung tumor diameter, alkaline phosphatase levels, pre-chemotherapy hCG levels, initial chemotherapy regimen, and whether hysterectomy was performed. Cox regression analysis highlighted that increased BMI was associated with a shorter time to hCG negativization (HR=1.730, P=0.001). In contrast, higher pre-treatment hCG levels, longer time since the last pregnancy, and undergoing hysterectomy were associated with prolonged hCG conversion times. In conclusion, this study underscores the importance of individual factors such as BMI, pre-treatment hCG levels, and surgical interventions in determining the duration of hCG negativization in GTN patients. These findings suggest that tailored treatment strategies considering these factors could enhance treatment efficacy and patient outcomes. Increased awareness and careful consideration of these factors should be integral to pre-treatment planning and patient counseling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.